EA200800182A1 - Циклические анилинопиридинотриазины в качестве ингибиторов gsk-3 - Google Patents

Циклические анилинопиридинотриазины в качестве ингибиторов gsk-3

Info

Publication number
EA200800182A1
EA200800182A1 EA200800182A EA200800182A EA200800182A1 EA 200800182 A1 EA200800182 A1 EA 200800182A1 EA 200800182 A EA200800182 A EA 200800182A EA 200800182 A EA200800182 A EA 200800182A EA 200800182 A1 EA200800182 A1 EA 200800182A1
Authority
EA
Eurasian Patent Office
Prior art keywords
6alkyl
4alkyl
het1
pyrrolidinyl
hydrogen
Prior art date
Application number
EA200800182A
Other languages
English (en)
Other versions
EA017545B1 (ru
Inventor
Фредерик Ян Рита Ромбаутс
Кристофер Джон Лав
Кристоф Ван Эмелен
Свен Францискус Анна Ван Брандт
Тонгфей Ву
Original Assignee
Янссен Фармацевтика Н. В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика Н. В. filed Critical Янссен Фармацевтика Н. В.
Publication of EA200800182A1 publication Critical patent/EA200800182A1/ru
Publication of EA017545B1 publication Critical patent/EA017545B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/16—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/14—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom
    • C07D251/16—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hydrogen or carbon atoms directly attached to at least one ring carbon atom to only one ring carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heat Sensitive Colour Forming Recording (AREA)

Abstract

Настоящее изобретение относится к соединениям формулы (I)их N-оксидным формам, фармацевтически приемлемым аддитивным солям и их стереохимически изомерным формам, где m представляет собой 1, n представляет собой 1, Z представляет собой N или С, в частности, N; Хпредставляет собой Салкил, в частности, метил; Xпредставляет собой Cалкил или Cалкил-NR-, в частности, пропил, -этил-NR- или -пропил-NR-; -Y- представляет собой -NR-C-алкил-CO-NR-, -Het-Салкил-СО-NR- или -HetCO-NR-, где -Cалкильный линкер в -NR-Cалкил-CO-NR- или -Het-Cалкил-CO-NR-необязательно замещен одним или, если это возможно, двумя или более заместителями, выбранными из гидрокси, галогена и фенила; Rпредставляет собой водород, хлор, фтор или бром; Rпредставляет собой -Салкил-, в частности, этил или метил; Rпредставляет собой водород; Rпредставляет собой водород; R, Rи Rпредставляют собой водород; Hetвыбран из пиперазинила или пиперидинила, в частности, представляет собой пиперазинил; Hetвыбран из пирролидинила или пиперидинила, в частности, пирролидинила, где указанный пирролидинил необязательно замещен гидрокси.
EA200800182A 2005-06-30 2006-06-26 Циклические анилино-пиридинотриазины в качестве ингибиторов gsk-3 EA017545B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP05105927 2005-06-30
PCT/EP2006/063555 WO2007003525A2 (en) 2005-06-30 2006-06-26 Cyclic anilino-pyridinotriazines as gsk-3 inhibitors

Publications (2)

Publication Number Publication Date
EA200800182A1 true EA200800182A1 (ru) 2009-04-28
EA017545B1 EA017545B1 (ru) 2013-01-30

Family

ID=37604825

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200800182A EA017545B1 (ru) 2005-06-30 2006-06-26 Циклические анилино-пиридинотриазины в качестве ингибиторов gsk-3

Country Status (20)

Country Link
US (1) US8778919B2 (ru)
EP (1) EP1904461B1 (ru)
JP (1) JP5345388B2 (ru)
KR (1) KR101268354B1 (ru)
CN (1) CN101341138B (ru)
AT (1) ATE439349T1 (ru)
AU (1) AU2006265205B2 (ru)
BR (1) BRPI0612888B8 (ru)
CA (1) CA2611438C (ru)
DE (1) DE602006008474D1 (ru)
EA (1) EA017545B1 (ru)
ES (1) ES2330789T3 (ru)
HK (1) HK1128086A1 (ru)
IL (1) IL188453A (ru)
NO (1) NO341531B1 (ru)
NZ (1) NZ564179A (ru)
TW (1) TWI457340B (ru)
UA (1) UA92608C2 (ru)
WO (1) WO2007003525A2 (ru)
ZA (1) ZA200711143B (ru)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL213783B1 (pl) 2002-03-13 2013-05-31 Janssen Pharmaceutica Nv Podstawiona pochodna piperydyny lub piperazyny, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
AU2003218735B2 (en) * 2002-03-13 2009-03-12 Janssen Pharmaceutica N.V. Piperazinyl-, piperidinyl- and morpholinyl-derivatives as novel inhibitors of histone deacetylase
CA2549869C (en) * 2003-12-18 2015-05-05 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
AU2005266312C1 (en) 2004-07-28 2011-06-16 Janssen Pharmaceutica N.V. Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
CA2605272C (en) 2005-05-18 2013-12-10 Janssen Pharmaceutica N.V. Substituted aminopropenyl piperidine or morpholine derivatives as novel inhibitors of histone deacetylase
US9074189B2 (en) 2005-06-08 2015-07-07 Janssen Biotech, Inc. Cellular therapy for ocular degeneration
CA2630717C (en) * 2006-01-19 2015-02-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
AU2007206944B2 (en) 2006-01-19 2012-08-23 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
ATE432272T1 (de) * 2006-01-19 2009-06-15 Janssen Pharmaceutica Nv Aminophenylderivate als neue inhibitoren von histondeacetylase
WO2007082882A1 (en) * 2006-01-19 2007-07-26 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
BRPI0714211B8 (pt) 2006-07-13 2021-05-25 Janssen Pharmaceutica Nv derivados de mtki quinazolina, sua utilização e composição farmacêutica que os compreende
BRPI0717618A2 (pt) 2006-10-21 2013-10-22 Abbott Gmbh & Co Kg Compostos heterocíclicos e uso dos mesmos como inibidores de glicogênio sintase quinase 3
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
CA2693715C (en) 2007-07-27 2015-10-27 Janssen Pharmaceutica Nv Pyrrolopyrimidines
DK2185693T3 (da) 2007-07-31 2019-09-23 Lifescan Inc Differentiering af humane embryoniske stamceller
KR101592182B1 (ko) 2007-11-27 2016-02-05 라이프스캔, 인코포레이티드 인간 배아 줄기 세포의 분화
RU2551772C2 (ru) 2008-02-21 2015-05-27 Сентокор Орто Байотек Инк. Способы, поверхностно-модифицированные носители и композиции для иммобилизации, культивирования и открепления клеток
CA2716079C (en) * 2008-03-10 2018-01-16 Janssen Pharmaceutica Nv 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors
EP2274288A2 (en) 2008-04-24 2011-01-19 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
EP2138488A1 (en) * 2008-06-26 2009-12-30 sanofi-aventis 4-(pyridin-4-yl)-1H-[1,3,5]triazin-2-one derivatives as GSK3-beta inhibitors for the treatment of neurodegenerative diseases
EP2310492B1 (en) * 2008-06-30 2015-07-22 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
EP2350265B1 (en) 2008-10-31 2019-04-17 Janssen Biotech, Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
CA2742268C (en) 2008-10-31 2020-02-18 Centocor Ortho Biotech Inc. Differentiation of human embryonic stem cells to the pancreatic endocrine lineage
RU2547925C2 (ru) 2008-11-20 2015-04-10 Сентокор Орто Байотек Инк. Способы и композиции для закрепления и культивирования клеток на плоских носителях
US20100124781A1 (en) 2008-11-20 2010-05-20 Shelley Nelson Pluripotent Stem Cell Culture on Micro-Carriers
WO2010085597A1 (en) * 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
AU2010276438B2 (en) 2009-07-20 2015-06-11 Janssen Biotech Inc. Differentiation of human embryonic stem cells
PL2456858T3 (pl) 2009-07-20 2019-01-31 Janssen Biotech, Inc Różnicowanie ludzkich embrionalnych komórek macierzystych
BR112012001564A2 (pt) 2009-07-20 2015-09-01 Janssen Biotech Inc Diferenciação de células tronco embrionárias humanas.
CN102712902B (zh) 2009-12-23 2019-01-08 詹森生物科技公司 人胚胎干细胞的分化
RU2610176C2 (ru) 2009-12-23 2017-02-08 Янссен Байотек, Инк. Дифференцировка человеческих эмбриональных стволовых клеток
WO2011109279A2 (en) 2010-03-01 2011-09-09 Centocor Ortho Biotech Inc. Methods for purifying cells derived from pluripotent stem cells
AU2011250912A1 (en) 2010-05-12 2012-11-22 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
US9528090B2 (en) 2010-08-31 2016-12-27 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
CA2809300A1 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
MX348537B (es) 2010-08-31 2017-06-07 Janssen Biotech Inc Diferencia de celulas madre pluripotentes.
JP5998142B2 (ja) 2010-09-27 2016-09-28 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのその使用
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
CA2860107C (en) 2011-12-22 2021-06-01 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
RU2664467C2 (ru) 2012-03-07 2018-08-17 Янссен Байотек, Инк. Среда определенного состава для размножения и обновления плюрипотентных стволовых клеток
RU2018108850A (ru) 2012-06-08 2019-02-26 Янссен Байотек, Инк. Дифференцировка эмбриональных стволовых клеток человека в панкреатические эндокринные клетки
KR102036780B1 (ko) 2012-12-31 2019-10-25 얀센 바이오테크 인코포레이티드 Hb9 조절제를 사용하는 인간 배아 줄기세포의 췌장 내분비 세포로의 분화
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
RU2768963C2 (ru) 2012-12-31 2022-03-25 Янссен Байотек, Инк. Культивация эмбриональных стволовых клеток человека в воздушно-жидкостной зоне взаимодействия с целью их дифференцировки в панкреатические эндокринные клетки
US10377989B2 (en) 2012-12-31 2019-08-13 Janssen Biotech, Inc. Methods for suspension cultures of human pluripotent stem cells
PT3702443T (pt) 2013-03-14 2022-02-17 Massachusetts Inst Technology Composições e métodos para expansão e cultura de células estaminais epiteliais
JP6401247B2 (ja) * 2013-05-06 2018-10-10 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ キナーゼ阻害剤としての大員環化合物
MA39823A (fr) * 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
MA39822A (fr) * 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
SG10201810739VA (en) 2014-05-16 2019-01-30 Janssen Biotech Inc Use of small molecules to enhance mafa expression in pancreatic endocrine cells
US10568883B2 (en) 2014-09-03 2020-02-25 Massachusetts Institute Of Technology Compositions, systems, and methods for generating inner ear hair cells for treatment of hearing loss
US10407442B2 (en) 2015-09-24 2019-09-10 Cyclenium Pharma Inc. Libraries of heteroaryl-containing macrocyclic compounds and methods of making and using the same
JP2019506153A (ja) 2016-01-08 2019-03-07 マサチューセッツ インスティテュート オブ テクノロジー 分化した腸内分泌細胞およびインスリン産生細胞の作製
US10213511B2 (en) 2016-03-02 2019-02-26 Frequency Therapeutics, Inc. Thermoreversible compositions for administration of therapeutic agents
US10201540B2 (en) 2016-03-02 2019-02-12 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I
US11260130B2 (en) 2016-03-02 2022-03-01 Frequency Therapeutics, Inc. Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV
MA45479A (fr) 2016-04-14 2019-02-20 Janssen Biotech Inc Différenciation de cellules souches pluripotentes en cellules de l'endoderme de l'intestin moyen
CN110392686A (zh) 2016-12-30 2019-10-29 频率治疗公司 1h-吡咯-2,5-二酮化合物以及使用它们来诱导干/祖支持细胞自我更新的方法
CA3066499A1 (en) * 2017-06-22 2018-12-27 Cyclenium Pharma Inc. Libraries of pyridine-containing macrocyclic compounds and methods of making and using the same
US11552262B2 (en) 2017-12-12 2023-01-10 Samsung Display Co., Ltd. Organic molecules for use in optoelectronic devices
US11617745B2 (en) 2018-08-17 2023-04-04 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by downregulating FOXO
AU2019321641A1 (en) 2018-08-17 2021-04-15 Frequency Therapeutics, Inc. Compositions and methods for generating hair cells by upregulating Jag-1
US20220133740A1 (en) 2019-02-08 2022-05-05 Frequency Therapeutics, Inc. Valproic acid compounds and wnt agonists for treating ear disorders
CN115010673B (zh) * 2022-07-21 2024-01-30 河南大学 可见光诱导无金属催化条件下合成1,3,5-三嗪类化合物的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442278A (en) * 1981-12-03 1984-04-10 Hughes Aircraft Company Ethynyl-substituted s-triazine derivatives, polymers thereof and process for making the same
ATE396978T1 (de) * 1999-10-07 2008-06-15 Amgen Inc Triazin-kinase-hemmer
US6864255B2 (en) * 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
CA2450167A1 (en) * 2001-06-12 2002-12-19 Elan Pharmaceuticals, Inc. Macrocycles useful in the treatment of alzheimer's disease
ES2575522T3 (es) 2002-07-18 2016-06-29 Janssen Pharmaceutica Nv Inhibidores de quinasas con triazina sustituida
DE10239042A1 (de) * 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
WO2004037814A1 (en) * 2002-10-25 2004-05-06 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
US20050014753A1 (en) * 2003-04-04 2005-01-20 Irm Llc Novel compounds and compositions as protein kinase inhibitors
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives

Also Published As

Publication number Publication date
BRPI0612888A2 (pt) 2010-12-07
JP2009500307A (ja) 2009-01-08
CA2611438C (en) 2014-01-07
IL188453A (en) 2012-06-28
JP5345388B2 (ja) 2013-11-20
AU2006265205B2 (en) 2011-06-30
BRPI0612888A8 (pt) 2017-12-26
ATE439349T1 (de) 2009-08-15
KR101268354B1 (ko) 2013-05-28
CN101341138A (zh) 2009-01-07
KR20080024223A (ko) 2008-03-17
BRPI0612888B8 (pt) 2022-12-27
DE602006008474D1 (de) 2009-09-24
NZ564179A (en) 2010-09-30
NO20080537L (no) 2008-03-28
BRPI0612888B1 (pt) 2020-12-29
EP1904461B1 (en) 2009-08-12
WO2007003525A2 (en) 2007-01-11
IL188453A0 (en) 2008-08-07
TW200740818A (en) 2007-11-01
HK1128086A1 (en) 2009-10-16
WO2007003525A3 (en) 2008-04-10
NO341531B1 (no) 2017-12-04
CA2611438A1 (en) 2007-01-11
CN101341138B (zh) 2012-11-14
ES2330789T3 (es) 2009-12-15
ZA200711143B (en) 2009-03-25
TWI457340B (zh) 2014-10-21
US8778919B2 (en) 2014-07-15
EP1904461A2 (en) 2008-04-02
UA92608C2 (en) 2010-11-25
EA017545B1 (ru) 2013-01-30
AU2006265205A1 (en) 2007-01-11
US20100222574A1 (en) 2010-09-02

Similar Documents

Publication Publication Date Title
EA200800182A1 (ru) Циклические анилинопиридинотриазины в качестве ингибиторов gsk-3
CY1119624T1 (el) Κρυσταλλικες μορφες του 4-μεθυλο-ν-[3-(4-μεθυλ-ιμιδαζολ-1-υλ)-5-τριφθορομεθυλο-φαινυλο] -3 -(4-πυριδιν-3-υλ-πυριμιδιν-2-υλαμινο)-βενζαμιδιου
UA112428C2 (uk) Пестицидні композиції і пов'язані з ними способи
ECSP088118A (es) Sales de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
DK1732933T3 (da) Forobindelser til behandling af dyslipidæmi
EA201390877A1 (ru) Замещенные 6,6-конденсированные азотсодержащие гетероциклические соединения и их применение
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
RS54587B1 (en) IMINOTIADIAZINE-DIOXIDE COMPOUNDS AS BACE, MIXTURE, AND USE INHIBITORS
UA98116C2 (ru) Изоксазолины, композиция, их применение, способы получения и промежуточные соединения
EA201170096A1 (ru) Замещенные производные пиримидона
EA200970605A1 (ru) Ингибиторы mapk/erk-киназ
CR8986A (es) Isoxazoles sustituidos como fungicidas
DK2134691T3 (da) Quinolinonderivativer som parp- og tank-inhibitorer
MX2016006685A (es) Compuestos heterociclicos de n-acilimino.
ATE478054T1 (de) Benzimidazolderivate
EA201791671A1 (ru) 4-замещенные соединения бензоксаборола и их применение
NO20071100L (no) 5-jodtetrazoler
MX370389B (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.
HRP20090011T3 (en) 2-oxo-1,2,4,5-tetrahydro-1,3-benzodiazepin-3-yl-piperidines used as cgrp antagonists
MX2015015058A (es) Nuevos compuestos de 3,4-dihidro-2h-isoquinolin-1-ona y 2,3-dihidro-isoindol-1-ona.
CY1114378T1 (el) Μεθοδος χρησιμοποιησης συνδυασμου παραγωγου βενζοφαινονης ή αλατος αυτου και ανοσοκατασταλτικου παραγοντα, και φαρμακευτικη συνθεση που περιλαμβανει αυτα τα συστατικα
WO2004007498A3 (en) 3-phenyl analogs of toxoflavine as kinase inhibitors
ECSP077378A (es) Isoxazoles sustituidos como fungicidas
TH91783B (th) ไซคลิค แอนิลิโน - พิริดิโนไทรแอซีน
TH126070B (th) สารอนุพันธ์ไพเพอราซินิลเอธิล 3-อะมิโนโพร์ลิดีน ในฐานะเป็นสารปฏิปักษ์ ccr2